Prostate Cancer - Results from #180

Prostate cancer and novel pharmacological treatment options - what's new for 2022? February 20, 2023

Rucaparib or Physician's Choice in Metastatic Prostate Cancer. February 20, 2023

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. February 20, 2023

Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. February 20, 2023

Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo. February 17, 2023

Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system. February 17, 2023

The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer. February 17, 2023

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. February 17, 2023

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. February 17, 2023

Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer. February 16, 2023

Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes. February 16, 2023

Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. February 16, 2023

The Role of mpMRI in the Assessment of Prostate Cancer Recurrence Using the PI-RR System: Diagnostic Accuracy and Interobserver Agreement in Readers with Different Expertise. February 16, 2023

Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer. February 16, 2023

A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). February 15, 2023

Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it. February 15, 2023

Age-stratified potency outcomes of bilateral nerve sparing robotic-assisted radical prostatectomy. February 15, 2023

Clinical, pathologic, and molecular features of amphicrine prostate cancer. February 15, 2023

Discrimination of Sexual and Gender Minority Patients in Prostate Cancer Treatment: Results from the Restore-1 Study. February 15, 2023

A randomized comparison of group mindfulness and group cognitive behavioral therapy vs control for couples after prostate cancer with sexual dysfunction. February 14, 2023

Page 10 of 1288